At SIMR we aspire to discover and develop differentiated therapeutics for the treatment of peripheral neuropathic pain. SIMR’s lead product, SR419, is a candidate drug with novel mechanism of action for the treatment of peripheral neuropathic pain, which is discovered and developed by SIMR. Peripheral neuropathic pain is the pain caused by damage or pathological changes of peripheral nerves, including post-herpetic neuralgia, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and postoperative peripheral neuropathy. The results of preclinical studies show that SR419 has excellent safety and pharmacokinetic properties. In addition, SR419 demonstrates the potential of better analgesic efficacy and fewer side effects than pregabalin, a commonly used first-line treatment for neuropathic pain. SR419 has completed phase I clinical trials in the Australia and China with positive safety results, and is planning to  carry out international multi-center phase II clinical trials.

At SIMR, we are focused on enrolling and conducting clinical trials aimed at gaining regulatory approval, making SR419 available to patients as quickly as possible. As such, we believe participation in our clinical trials is the most appropriate way to access SR419 at this stage of development. Information about our clinical trials, including eligibility criteria and locations, is available at www.clinicaltrials.gov.

SIMR understands the interest of patients in accessing SR419 outside of clinical trials and prior to regulatory approval for potentially life threatening diseases, however we do not currently offer any Expanded Access programs for SR419.

SIMR recognizes the need for Expanded Access programs and will re-evaluate the status of our policy based on data from ongoing and future clinical trials.